Related Experiment Video
Updated: Aug 20, 2025

Lumbar Intrathecal Injection of Gene Therapy Vectors for Central Nervous System Targeting in Mice and Rats
Published on: May 16, 2025
An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding
1Clinical Associate Professor, University of Michigan College of Pharmacy, Ann Arbor, Michigan, amberg@med.umich.edu.
Abstract:
There are now 9 available FDA-approved second-generation long-acting injectable antipsychotics including aripiprazole (3), olanzapine (1), paliperidone (3), and risperidone (2). These high-cost medications are commonly used with the goal of improving adherence and patient outcomes. With almost 2 decades of use, key aspects have been well studied, including population pharmacokinetics, CYP interactions and various clinical and economic outcomes. However, there are still unknowns with these medications. Issues including adherence, transition from oral antipsychotics, renal dosing, pharmacogenomics, and managing missed doses will be addressed in the context of 4 patient cases.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Psychosis and Antipsychotic Drugs: Overview
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

